Welcome to our dedicated page for Novavax SEC filings (Ticker: NVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novavax, Inc. (NASDAQ: NVAX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Novavax is a vaccine-focused biotechnology company that reports on its financial condition, material agreements, capital structure and key product and partnership developments through forms such as 10-K, 10-Q and 8-K.
Current Reports on Form 8-K for Novavax frequently address material events tied to its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, the Matrix-M® adjuvant platform and major collaborations. Examples include disclosures about the collaboration and license agreement with Sanofi, marketing authorization transfers for Nuvaxovid in the European Union and United States that trigger milestone payments, amendments expanding Sanofi’s license to use Matrix-M in pandemic influenza vaccine candidates, and milestone payments and royalties associated with partners such as Takeda. Other 8-K filings describe site consolidation transactions in Maryland, non-cash impairment charges, and convertible senior note exchanges and issuances that shape the company’s capital structure.
Periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide detail on Novavax’s revenue components, including product sales, supply sales and licensing, royalties and other revenue, as well as research and development and selling, general and administrative expenses. They also expand on risk factors related to regulatory approvals, manufacturing, partnerships and market adoption of its vaccines.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in clear language. Users can quickly see key points from lengthy 10-K and 10-Q reports, understand the impact of 8-K announcements on partnerships and financing, and review information about potential equity issuance and debt obligations, including convertible senior notes. The filings page also surfaces insider and executive-related filings, such as Forms 3, 4 and 5, when available, to help track equity ownership changes.
All documents are updated in near real time as they are posted to the SEC’s EDGAR system, allowing investors and researchers to review Novavax’s official disclosures, assess how collaboration agreements and regulatory decisions affect the business, and follow the evolution of its vaccine and adjuvant platform through formal reporting.
Novavax’s executive vice president and chief legal officer reported equity award activity involving company stock. On 12/11/2025, the executive acquired 41,899 shares of Novavax common stock at $0 per share, increasing direct ownership to 73,972 shares immediately after that transaction.
On the same date, a separate transaction coded “F” shows the disposition of 12,713 shares at a price of $6.69 per share, leaving the executive with 61,159 shares of common stock held directly. The filing also lists 41,899 restricted stock units tied to Novavax common stock at a $0 exercise price, with a vesting schedule under which one-third of the RSUs vest on each of the first three anniversaries of the grant date, subject to continued employment.
Novavax (NVAX) officer reported equity transactions on 11/11/2025. 14,257 shares of common stock were acquired at $0.00 via RSU conversion (Code M), and 6,048 shares were sold to cover taxes at $7.40 (Code F). After these transactions, 8,209 common shares were held directly.
The filing lists RSU activity tied to these shares and shows 28,513 restricted stock units beneficially owned following the transactions. Each RSU represents one share, with vesting at one‑third on each of the first three anniversaries of the grant date, subject to continued employment.
Novavax, Inc. (NVAX) reported an update on results. The company furnished an 8-K stating it issued a press release with its financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. This filing formally notifies the market of the availability of the company’s Third Quarter financial information.
Novavax (NVAX) filed its Q3 2025 10‑Q, reporting total revenue of
Operating results reflected an
Cash and cash equivalents were
Novavax announced that the U.S. Food and Drug Administration approved the transfer of the marketing authorization for Nuvaxovid from Novavax to Sanofi Pasteur Inc.
The approval triggers a $25 million milestone payment from Sanofi to Novavax under their Collaboration and License Agreement. The company anticipates receiving this payment in the first quarter of 2026.
Novavax also furnished a press release detailing the update. The filing includes customary forward-looking statements language outlining regulatory and operational risks that could affect future outcomes.
Novavax (NVAX) director reported an equity acquisition. On 10/29/2025, the reporting person acquired 3,800 shares of common stock through the settlement of restricted stock units (transaction code M). Following the transaction, the director beneficially owned 28,490 shares directly.
The RSUs were granted under the Company’s Amended and Restated 2015 Stock Incentive Plan and vest in three equal annual installments on each anniversary of the 10/29/2022 grant date, subject to continued employment. The derivative line shows 3,800 RSUs converted at $0.00 with 0 RSUs remaining from this grant after the transaction.
Novavax entered into agreements with AstraZeneca to assign the lease of its former headquarters at 700 Quince Orchard Road, Gaithersburg, MD, and to sell adjacent land and on-site assets. The transactions will result in an aggregate of $59.8 million payable by AstraZeneca, including a $15.0 million lease assignment fee, a $20.0 million purchase of approximately 9.7 acres of land, and a $24.8 million asset sale with a $4.0 million deposit held in escrow.
The lease assignment, covering approximately 171,239 rentable square feet through December 2036, is subject to landlord consent and an amended lease, both effective January 5, 2026. Novavax will pay base rent from January 5, 2026 through June 30, 2026. Cash receipts are expected with the $20.0 million parcel closing in Q4 2025 and the balance of approximately $39.8 million in Q1 2026.
Novavax expects total non-cash charges of $125–$127 million in Q3 2025, including an estimated $96–$98 million impairment tied to asset write-offs (partially offset by a land-sale gain) and a $29 million charge from extinguishing 5.00% Convertible Senior Notes due 2027. The company has relocated its corporate headquarters to 21 Firstfield Road, Gaithersburg, MD.
Novavax, Inc. filed an 8-K disclosing an indenture with The Bank of New York Mellon Trust Company, N.A. as trustee and included the form of 4.625% Convertible Senior Notes due 2031 as an exhibit. The filing also references embedded cover page Inline XBRL tags and is signed on behalf of the company by Mark J. Casey, Executive Vice President and Chief Legal Officer. The material provides the legal framework and note terms for a potential convertible debt instrument but does not state offering size, pricing beyond the stated coupon, conversion mechanics, or use of proceeds.
FAQ
What is the current stock price of Novavax (NVAX)?
What is the market cap of Novavax (NVAX)?
